MX2020013557A - Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y métodos de uso del mismo. - Google Patents
Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y métodos de uso del mismo.Info
- Publication number
- MX2020013557A MX2020013557A MX2020013557A MX2020013557A MX2020013557A MX 2020013557 A MX2020013557 A MX 2020013557A MX 2020013557 A MX2020013557 A MX 2020013557A MX 2020013557 A MX2020013557 A MX 2020013557A MX 2020013557 A MX2020013557 A MX 2020013557A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- disubstituted
- pyrazolyl steroid
- subject
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862684155P | 2018-06-12 | 2018-06-12 | |
| US201962789329P | 2019-01-07 | 2019-01-07 | |
| US201962841645P | 2019-05-01 | 2019-05-01 | |
| PCT/US2019/036848 WO2019241442A1 (en) | 2018-06-12 | 2019-06-12 | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020013557A true MX2020013557A (es) | 2021-05-27 |
Family
ID=67211854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020013557A MX2020013557A (es) | 2018-06-12 | 2019-06-12 | Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y métodos de uso del mismo. |
Country Status (13)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2806877T3 (pl) | 2012-01-23 | 2020-06-01 | Sage Therapeutics, Inc. | Formulacje neuroaktywnego steroidu zawierające kompleks allopregnanolonu i eteru sulfobutylowego beta-cyklodekstryny |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| LT3224269T (lt) | 2014-11-27 | 2020-07-10 | Sage Therapeutics, Inc. | Kompozicijos ir būdai, skirti cns sutrikimams gydyti |
| IL302480A (en) | 2016-08-23 | 2023-06-01 | Sage Therapeutics Inc | 19-NOR C3, 3-Dimuter C21-N-Pyrazolyl Steroid Crystalline |
| WO2019113494A1 (en) | 2017-12-08 | 2019-06-13 | Sage Therapeutics, Inc. | Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders |
| AU2020395246A1 (en) * | 2019-12-05 | 2022-06-16 | Sage Therapeutics, Inc. | A 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid and methods of use thereof |
| CA3176854A1 (en) | 2020-03-25 | 2021-09-30 | Sage Therapeutics, Inc. | Use of agents for treatment of respiratory conditions |
| BR112023000990A2 (pt) * | 2020-07-20 | 2023-03-28 | Sage Therapeutics Inc | Formulações de esteroide c21-n-pirazolil 19-nor c3,3- dissubstituído e métodos de uso das mesmas |
| JP2024510436A (ja) * | 2021-03-17 | 2024-03-07 | セージ セラピューティクス， インコーポレイテッド | 大うつ病性障害の処置のための１９－ノルｃ３，３－２置換ｃ２１－ｎ－ピラゾリルステロイド |
| JP2024515830A (ja) * | 2021-04-29 | 2024-04-10 | セージ セラピューティクス， インコーポレイテッド | 母乳を出している女性における大うつ病性障害および産後うつ病の処置における使用のための神経活性ステロイド |
| KR20240006026A (ko) * | 2021-04-29 | 2024-01-12 | 세이지 테라퓨틱스, 인크. | 주요 우울 장애 및 산후 우울증을 치료하는 데 사용하기 위한 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 |
| WO2023158668A1 (en) * | 2022-02-16 | 2023-08-24 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of cns-related disorders |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201508550XA (en) * | 2013-04-17 | 2015-11-27 | Sage Therapeutics Inc | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof |
| JOP20200195A1 (ar) * | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| PL3206493T3 (pl) * | 2014-10-16 | 2021-01-25 | Sage Therapeutics, Inc. | Kompozycje i sposoby leczenia zaburzeń OUN |
| MA43815A (fr) * | 2016-03-08 | 2021-04-07 | Sage Therapeutics Inc | Stéroïdes neuroactifs, compositions, et leurs utilisations |
| IL302480A (en) * | 2016-08-23 | 2023-06-01 | Sage Therapeutics Inc | 19-NOR C3, 3-Dimuter C21-N-Pyrazolyl Steroid Crystalline |
| TW202342058A (zh) * | 2017-09-07 | 2023-11-01 | 美商賽吉醫療公司 | 神經活性類固醇及其使用方法 |
-
2019
- 2019-06-12 CN CN202410051762.8A patent/CN117959309A/zh active Pending
- 2019-06-12 MA MA052894A patent/MA52894A/fr unknown
- 2019-06-12 CA CA3103421A patent/CA3103421A1/en active Pending
- 2019-06-12 JP JP2020569024A patent/JP2021527092A/ja active Pending
- 2019-06-12 AU AU2019287491A patent/AU2019287491A1/en active Pending
- 2019-06-12 SG SG11202012344RA patent/SG11202012344RA/en unknown
- 2019-06-12 TW TW108120367A patent/TW202005653A/zh unknown
- 2019-06-12 WO PCT/US2019/036848 patent/WO2019241442A1/en unknown
- 2019-06-12 CN CN201980051843.5A patent/CN112533611A/zh active Pending
- 2019-06-12 KR KR1020217000726A patent/KR20210021005A/ko unknown
- 2019-06-12 US US17/251,475 patent/US20210338692A1/en active Pending
- 2019-06-12 EP EP19737327.7A patent/EP3806863A1/en active Pending
- 2019-06-12 MX MX2020013557A patent/MX2020013557A/es unknown
- 2019-12-05 US US16/704,800 patent/US20200113917A1/en not_active Abandoned
-
2020
- 2020-12-09 IL IL279315A patent/IL279315A/en unknown
-
2022
- 2022-06-17 US US17/843,031 patent/US20220323462A1/en active Pending
-
2023
- 2023-12-05 JP JP2023205211A patent/JP2024028849A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MA52894A (fr) | 2021-04-21 |
| US20210338692A1 (en) | 2021-11-04 |
| JP2021527092A (ja) | 2021-10-11 |
| CA3103421A1 (en) | 2019-12-19 |
| IL279315A (en) | 2021-01-31 |
| JP2024028849A (ja) | 2024-03-05 |
| SG11202012344RA (en) | 2021-01-28 |
| CN117959309A (zh) | 2024-05-03 |
| US20200113917A1 (en) | 2020-04-16 |
| CN112533611A (zh) | 2021-03-19 |
| AU2019287491A1 (en) | 2021-01-07 |
| US20220323462A1 (en) | 2022-10-13 |
| TW202005653A (zh) | 2020-02-01 |
| KR20210021005A (ko) | 2021-02-24 |
| WO2019241442A1 (en) | 2019-12-19 |
| EP3806863A1 (en) | 2021-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020013557A (es) | Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y métodos de uso del mismo. | |
| MX2022006533A (es) | Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y metodos de uso del mismo. | |
| PH12020551425A1 (en) | Rimegepant for cgrp related disorders | |
| PH12018502634A1 (en) | Topical compositions of apremilast | |
| MX2023010064A (es) | Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y metodos de uso del mismo. | |
| SG10201811841UA (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| WO2019006005A3 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA | |
| PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
| MX2021005075A (es) | Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion. | |
| MX2018009173A (es) | Uso de estimuladores de guanilato ciclasa soluble (sgc) para el tratamiento de esteatohepatitis no alcohólica (nash). | |
| MX2021003773A (es) | Composiciones farmacéuticas y métodos relacionados con los agentes terapéuticos óticos. | |
| CR20220215A (es) | Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1 | |
| MX2018004309A (es) | Terapias combinadas para tratar el cancer. | |
| WO2018143552A3 (ko) | 탈모방지 또는 발모촉진용 주사용 조성물 | |
| MX2020011817A (es) | Metodos para tratar el linfoma. | |
| EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
| CR20220329A (es) | Anticuerpos anti–mertk y metodos de uso de los mismos | |
| WO2019157495A3 (en) | Methods for preventing and/or treating bone loss conditions by modulating irisin | |
| CR20220216A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 | |
| MX2021013354A (es) | Metodos para tratar y/o prevenir queratosis actinica. | |
| MX2021010989A (es) | Formulacion que incluye una combinacion de la hormona beta-endorfina y adrenocorticotropica. | |
| EP3991749A3 (en) | A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody | |
| ZA202104166B (en) | Sulcardine administration for treatment of acute atrial fibrillation | |
| JOP20220160A1 (ar) | مركبات فعّالة نحو مستقبلات نووية | |
| MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. |